Iannone, Luigi Francesco
Vaghi, Gloria
Sebastianelli, Gabriele
Casillo, Francesco
Russo, Antonio
Silvestro, Marcello
Pistoia, Francesca
Volta, Giorgio Dalla
Cortinovis, Matteo
Chiarugi, Alberto
Montisano, Danilo Antonio
Prudenzano, Maria Pia
Cevoli, Sabina
Mampreso, Edoardo
Avino, Gianluca
Romozzi, Marina
Valente, Mariarosaria
Fasano, Carla
Battistini, Stefania
Granato, Antonio
Piella, Elisa Maria
Rainero, Innocenzo
Ornello, Raffaele
De Icco, Roberto
,
Mascarella, Davide
Bolchini, Matteo
Saporito, Gennaro
Grazzi, Licia
Marcinnò, Andrea
Garascia, Gabriele
Grassi, Enrico
Vollono, Catello
Boscain, Francesca
Gentile, Martino
Burgalassi, Andrea
De Santis, Federico
Corrado, Michele
Sances, Grazia
Tassorelli, Cristina
Albanese, Maria
Trimboli, Michele
Doretti, Alberto
Article History
Received: 20 September 2024
Accepted: 3 December 2024
First Online: 6 January 2025
Declarations
:
: The study was approved as a part of the <i>Registro Italiano Cefalee (RICe)</i> study by the local Ethics Committee (CEAVC Studio RICe, 14591_oss and subsequent amendments 2022–609; 2023).
: LFI received fees and Honoraria for advisory boards, speaker panels from Teva, Eli Lilly, Lundbeck, Pfizer and AbbVie. GV received personal fees from Lundbeck; M.S has received speaker honoraria from Novartis, Teva, and Lilly; AR has received speaker honoraria from Allergan, Lilly, Novartis, Biogen, and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session); SC received honoraria for speaker panels from Teva and Novartis; MPP received speaker honoraria and advisory board participation from Abbvie, Idorsia, Eli-Lilly, Novartis, Pfizer, TEVA; RO reports personal fees and non-financial support from Allergan-AbbVie, Eli Lilly, Novartis, Pfizer, and Teva; RDI reports personal fees and non-financial support from Eli-Lilly, AbbVie, Pfizer, Lundbeck, and TEVA. Other authors have no conflicting interests on this specific study.